RESEARCH ARTICLE The evaluation of anti-ang o

Full list of author information is available at the end of the articlePrimary hepatocellular carcinoma is one of the most com-mon gastrointestinal cancers. Having portal vein tumor thrombus (PVTT) is considered one of the main indicators for poor prognosis in liver cancer due to higher likelihood of intrahepatic and distant metastasis [1]. Current treat-ments for hepatocellular carcinoma with PVTT include which targeted anti-angiogenic drug therapy is becom-ing a popular research topic. Endostar is the generic name for recombinant human endostatin injection agent. It binds to the VEGF receptor on the tumor vascular epi-thelial cells, inhibits tumor angiogenesis, and blocks nutri-ent supply to tumor cells. However, current evaluation of treatment effect for PVTT is generally based on patients’ median survival, an objective and non-invasive metho